Larval therapy, also called maggot debridement therapy, is one of the oldest biological approaches to wound care: sterile, laboratory-reared fly larvae are applied to a wound to remove devitalized tissue, reduce bacterial burden, and support healing. In diabetic foot ulcers (DFUs), where non-viable tissue and infection often delay healing, the technique has a long clinical history. The more useful question today is how strong the supporting evidence actually is.
What larval therapy is meant to do
Live larvae of Lucilia sericata are placed in the wound, either loose under a retaining dressing or enclosed in a mesh bag, and left for roughly two to three days. They digest necrotic tissue and slough while sparing viable tissue. A 2020 systematic review protocol in BMJ Open (PROSPERO CRD42020176953) describes the premise as the belief that larvae debride wounds more effectively and safely than standard treatments. The protocol itself reports no results; it sets out planned outcomes of complete healing, time to healing, change in wound area, and adverse events including infection, pain, and amputation. That the review was needed highlights how unsettled the question remains.
What the trials and reviews found
The Cochrane review of debridement for diabetic foot ulcers (Edwards and Stapley, 2010) identified six randomized trials of debridement methods. Four tested hydrogels, one compared larval therapy with hydrogel, and one assessed surgical debridement. The larval trial was described as small; it suggested a greater than 50% reduction in wound area with larvae compared with hydrogel, and the reviewers concluded that larval therapy produced a significantly greater reduction in wound area. In the same review, pooled hydrogel trials showed a higher healing rate than gauze or standard care (relative risk 1.84, 95% CI 1.3 to 2.61), whereas surgical debridement showed no significant benefit over standard treatment.
The most frequently cited clinical study of larvae in diabetic wounds is a case-control analysis by Armstrong and colleagues in the Journal of the American Podiatric Medical Association (2005). It followed 60 nonambulatory patients with neuroischemic DFUs (University of Texas grade C or D) and peripheral vascular disease over six months. Healing occurred in 57% of the maggot group versus 33% of controls, a difference that was not statistically significant. Among patients who healed, time to healing was shorter with larvae (18.5 versus 22.4 weeks). High-level amputation occurred in 10% of the maggot group versus 33% of controls, and antibiotic-free days were higher with larvae (126.8 versus 81.9). Infection rates (60% versus 80%) did not differ significantly. The authors described the findings as evidence of potential efficacy and concluded that larvae reduce short-term morbidity in this population.
How current guidelines treat larval therapy
The 2023 International Working Group on the Diabetic Foot (IWGDF) guideline on interventions to enhance healing of foot ulcers in diabetes (Chen et al., Diabetes/Metabolism Research and Reviews, 2024) restricted its evidence review to randomized controlled trials. For autolytic, biosurgical, hydrosurgical, chemical, and laser debridement, it found no randomized trials meeting its inclusion criteria. Larval therapy falls within the biosurgical group, and the guideline recommends against using these methods in place of standard care, a strong recommendation based on low-certainty evidence. Standard care, meaning sharp debridement by a trained clinician, remains the reference approach, with debridement frequency determined by clinical need. The guideline also states more broadly that the certainty of much of the evidence in wound healing remains poor.
Interpreting the evidence
Two points stand out. First, the signals that exist are favorable but fragile: one small randomized comparison with hydrogel, and one non-randomized case-control study in a specific high-risk population. Second, guideline groups that apply strict trial-based criteria have not been able to grade larval therapy at all. Absence of high-quality trials is not evidence of harm or of ineffectiveness, but it limits how confidently the approach can be generalized. Practical considerations, including patient acceptance, availability of medical-grade larvae, and suitability for wounds with adequate perfusion and limited access for sharp debridement, are matters for individual clinical judgment.
Key takeaways
Larval therapy is a biologically plausible debridement method with limited but suggestive evidence in diabetic foot ulcers. A small Cochrane-reviewed trial found greater wound area reduction than hydrogel, and a case-control study in neuroischemic patients suggested fewer high-level amputations and more antibiotic-free days. Neither provides the certainty of large randomized trials, and the 2023 IWGDF guideline found no eligible randomized evidence to support biosurgical debridement over sharp debridement as standard care. Better-designed trials are needed to define where, if anywhere, larval therapy offers a measurable advantage.
References
- Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews. 2010;(1):CD003556.
- Armstrong DG, Salas P, Short B, Martin BR, Kimbriel HR, Nixon BP, Boulton AJM. Maggot therapy in “lower-extremity hospice” wound care: fewer amputations and more antibiotic-free days. Journal of the American Podiatric Medical Association. 2005;95(3):254-257.
- Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.
- Systematic review and meta-analysis protocol on larval therapy for leg ulcers including diabetic foot ulcers (PROSPERO CRD42020176953). BMJ Open. 2020;10(10):e039898.
- Suraya AS, Kurniawati ND, Mariyanti H, Suarilah I. A systematic review of efficacy on larva debridement in diabetic foot ulcers. Healthcare in Low-resource Settings. 2024.
Comments
